HC Wainwright Issues Pessimistic Forecast for ACTU Earnings

Actuate Therapeutics, Inc. (NASDAQ:ACTU) – Investment analysts at HC Wainwright cut their FY2030 earnings estimates for shares of Actuate Therapeutics in a report issued on Monday, May 18th. HC Wainwright analyst S. Ramakanth now expects that the company will post earnings per share of $1.24 for the year, down from their prior forecast of $1.35. HC Wainwright has a “Buy” rating and a $15.00 price objective on the stock. The consensus estimate for Actuate Therapeutics’ current full-year earnings is ($0.80) per share.

Actuate Therapeutics (NASDAQ:ACTU) last released its earnings results on Thursday, May 14th. The company reported ($0.24) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.23) by ($0.01).

A number of other analysts also recently issued reports on the stock. Wall Street Zen upgraded shares of Actuate Therapeutics from a “sell” rating to a “hold” rating in a report on Saturday, April 4th. Weiss Ratings restated a “sell (e+)” rating on shares of Actuate Therapeutics in a report on Friday, March 27th. Two equities research analysts have rated the stock with a Buy rating and one has given a Sell rating to the company. Based on data from MarketBeat, Actuate Therapeutics currently has a consensus rating of “Hold” and an average price target of $17.50.

Actuate Therapeutics Price Performance

Shares of NASDAQ ACTU opened at $2.43 on Tuesday. The company has a 50 day simple moving average of $2.55 and a 200-day simple moving average of $4.62. The company has a market capitalization of $58.15 million, a P/E ratio of -2.51 and a beta of 0.92. Actuate Therapeutics has a 1 year low of $1.58 and a 1 year high of $11.99.

Institutional Trading of Actuate Therapeutics

Institutional investors have recently added to or reduced their stakes in the stock. ABS Direct Equity Fund LLC acquired a new stake in Actuate Therapeutics in the 4th quarter valued at approximately $40,000. Deutsche Bank AG increased its holdings in Actuate Therapeutics by 640.0% in the 4th quarter. Deutsche Bank AG now owns 9,309 shares of the company’s stock valued at $57,000 after purchasing an additional 8,051 shares during the last quarter. Barclays PLC increased its holdings in Actuate Therapeutics by 68.6% in the 4th quarter. Barclays PLC now owns 14,946 shares of the company’s stock valued at $91,000 after purchasing an additional 6,081 shares during the last quarter. Bank of America Corp DE increased its holdings in Actuate Therapeutics by 61,068.0% in the 2nd quarter. Bank of America Corp DE now owns 15,292 shares of the company’s stock valued at $93,000 after purchasing an additional 15,267 shares during the last quarter. Finally, Jane Street Group LLC acquired a new stake in Actuate Therapeutics in the 4th quarter valued at approximately $102,000.

About Actuate Therapeutics

Actuate Therapeutics (NASDAQ: ACTU) is a clinical-stage oncology company focused on the discovery and development of targeted therapies designed to address key drivers of tumor growth and survival. Headquartered in South San Francisco, California, the company applies a precision medicine approach to identify novel molecular targets and develop small-molecule agents that have the potential to improve outcomes for patients with difficult-to-treat cancers.

The company’s lead asset, atuveciclib, is a selective, oral CDK9 inhibitor being evaluated in a Phase 1 clinical trial for patients with acute myeloid leukemia and advanced solid tumors.